“PROFOL” since April 1998 through its predecessor, Haematal Biologicals Ltd. It is contended that the said predecessor of the petitioner had conceived and adopted the trade mark “PROFOL” independently and honestly from the ingredient molecule Propofol. Therefore, such adoption of the trade mark by the petitioner’s predecessor was honest, independent and was not with any knowledge of the respondent no.1’s trade mark “ROFOL”. It is contended that the petitioner’s said predecessor used to get its medicinal and pharmaceutical preparations manufactured under the trade mark “PROFOL” on a loan license basis from its common law licensee, Core Laboratories Ltd. Core Laboratories had accordingly on 22.4.1998 applied to Food & Drug authorities for grant of manufacturing license for its formulation, propofol injection I.V. and had thus been manufacturing and marketing the said goods under the trade mark “PROFOL” since the years 1998 as licensee of the petitioner’s predecessor, Haematal Biologicals Ltd. Vide a licence agreement dated 1.4.1999, the petitioner’s predecessor licensed the use of its trade mark “PROFOL” to Claris Lifesciences Ltd. On 17.2.2000 the running business of the petitioner’s predecessor, Haematal Biologicals Ltd., was amalgamated with the petitioner and all properties, assets, rights including intellectual property rights in the trade mark “PROFOL” amongst others